Adult asthma: Luforbec 100/6 & 200/6 are indicated in the regular treatment of asthma in adults where use of a combination ICS/LABA is appropriate.2,3 Luforbec 100/6 is licenced for use as Maintenance and Reliever Therapy (MART) in appropriate adult asthma patients.2
COPD: Luforbec 100/6 is indicated for symptomatic treatment of patients with severe COPD (FEV1<50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.2
Luforbec offers an NHS List Price saving of 52% vs Fostair 100/6 and 200/6 pMDI1
Prescribing Luforbec by brand could deliver cost improvements of up to £105.8 million per year across the UK4
Luforbec has released list price savings of £31,383,023, for the NHS and is now the most widely prescribed beclometasone/formoterol pMDI in 26 ICBs and Health Boards across the UK, up to August 20245
Beclometasone/Formoterol pMDIs are listed as Category C medicines in the NHS Drug Tariff, therefore Luforbec must be prescribed by brand to release savings for the NHS1
If you would like to know more about Luforbec and the savings opportunities available, please get in touch by email to:
UKRespiratory@lupin.com or call on: 01565 751378
Through carbon offsetting Luforbec 100/6 and 200/6 pMDI are certified as Carbon Neutral products.6,7
To read more about how carbon neutrality for Luforbec is achieved, click here.
